Details

Autor(en) / Beteiligte

• Avila, Edward K
• Chamberlain, Marc
• Schiff, David
• Reijneveld, Jaap C
• Armstrong, Terri S
• Ruda, Roberta
• Wen, Patrick Y
• Weller, Michael
• Koekkoek, Johan A F
• Mittal, Sandeep
• Arakawa, Yoshiki
• Choucair, Ali
• Gonzalez-Martinez, Jorge
• MacDonald, David R
• Nishikawa, Ryo
• Shah, Aashit
• Vecht, Charles J
• Warren, Paula
• van den Bent, Martin J
• DeAngelis, Lisa M

Titel

Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials

Ist Teil von

• Neuro-oncology (Charlottesville, Va.), 2017-01, Vol.19 (1), p.12-21

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2017

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy. A review of the current literature regarding seizure assessment for low-grade glioma patients reveals a heterogeneous manner in which seizure response has been reported. There is a need for a systematic approach to seizure assessment and its influence on health-related quality-of-life outcomes in patients enrolled in low-grade glioma therapeutic trials. In view of the need to have an adjunctive metric of tumor response in these patients, a method of seizure assessment as a metric in brain tumor treatment trials is proposed.